Traditionally, a variety of factors were used to make adjuvant treatment decisions in breast cancer, but none of those factors, except grade, has a consistent association with sensitivity to chemotherapy or endocrine therapy. However, oncologists now are able to use molecular assays as a component of decision making for adjuvant therapy. This article focuses on the use of two of those molecular assays and their implications for nurses.